Journal of Pregnancy / 2010 / Article / Tab 3

Research Article

Antenatal Steroid Therapy for Fetal Lung Maturation and the Subsequent Risk of Childhood Asthma: A Longitudinal Analysis

Table 3

Association between antenatal steroid therapy exposure and childhood asthma.

AdjustedUnadjusted
HR95% CIHR95% CI

Antenatal steroid exposure
 3–5 years1.191.03–1.391.551.36–1.77
 6–7 years1.060.86–1.301.361.12–1.65
 8+ years0.740.54–1.030.980.72–1.34

Male gender 1.241.21–1.28
Preterm birth (<37 weeks) 1.030.95–1.12

Number of siblings 
 01.00
 10.900.88–0.93
 20.780.74–0.82
 3+0.670.62–0.72

Bronchopulmonary Dysplasia 0.980.74–1.31
Hyaline Membrane Disease 1.141.01–1.30
Surfactant Administration 1.070.82–1.40

1 Minute Apgar Score 
 0–31.00
 4–60.950.86–1.05
 7–100.870.79–0.95

Caesarean section 1.111.07–1.15
Maternal smoking 1.121.09–1.16
Birth weight (per 500 grams) 1.000.98–1.01
Gestational age (weeks) 0.970.96–0.98

Birth year 
 19891.471.37–1.59
 19901.451.35–1.56
 19911.491.39–1.60
 19921.281.19–1.37
 19931.211.12–1.30
 19941.141.06–1.23
 19951.121.04–1.20
 19960.990.92–1.07
 19971.020.95–1.11
 19981.00

Note: Adjustment for all other confounders in table.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.